FDA panel backs speedy approval for Merck HIV drug

Share this article:

An FDA appointed panel of outside medical experts has unanimously backed the accelerated approval of Merck's new first-in-class HIV drug Isentress (raltegravir) for patients who have failed treatment with other HIV drugs.

Under the accelerated approval process, time is trimmed off the standard approval period for compounds deemed an advance over existing therapies by the FDA.

In June, the FDA granted Merck's Isentress application priority review status, indicating the drug addresses an urgent medical need. As a result, Isentress' review time was "fast-tracked" to six months, instead of the 10 months the process often takes under standard review.

The FDA usually follows the recommendations of its advisory panels, although it isn't required to do so.

If approved, Isentress would be the first in a new class of antiretroviral agents called integrase inhibitors that inhibit the insertion of HIV DNA into human DNA.

Inhibiting integrase from performing this function blocks the ability of the virus to replicate and infect new cells. There are drugs in use that inhibit two other enzymes critical to the HIV replication process -- protease and reverse transcriptase -- but currently no approved drugs inhibit integrase.

The drug is designed to be used in combination with other AIDS treatments, although the panel did not specify which drugs should be used with Isentress.

Merck estimates that between 20,000 and 40,000 US HIV patients would qualify to take Isentress if it is approved.

Joe Tooley, an analyst for A.G. Edwards, said in a published report that sales for Isentress could reach $750 million in annual sales by 2011.

Last month, the FDA granted approval to Pfizer's Selzentry (maraviroc) HIV treatment, another first-in-class HIV treatment. Selzentry works by blocking viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV. Selzentry was granted approval under priority review status. Analysts have projected sales of Selzentry to reach $500 million by 2011.

Meanwhile, Johnson & Johnson is awaiting FDA approval for its new AIDS drug known as TMC-125, also designed to be used by patients who have failed treatment with other HIV drugs.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...